IHVR-19029 is an effective endoplasmic reticulum (ER) α-glucosidases I and II inhibitor (IC50: 0.48 μM for ER a-glucosidase I). IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Ebola virus, Dengue virus, and Rift Valley fever virus.

The combination of IHVR-19029 and Favipiravir synergistically inhibits the replication of Yellow fever and Ebola viruses in cultured cells[4]. IHVR-19029 efficiently inhibits Bovine viral diarrhea virus (BVDV), Tacaribe virus (TCRV) and Dengue virus (DENV) (EC50s: 0.25, 0.74, and 1.25 μM, respectively)[2].

IHVR-19029 (75/5/5 mg/kg; p.o./i.m./i.p.) shows AUC values of 945/1839/983 μg*h/mL, Cmax values of 0.26/1.23/1.33 μg/ml, Tmax values of 2.1/0.1/0.17 hours, and F values of 4.6/ 71/133%, respectively. IHVR-19029 (5 mg/kg; i.v.) has AUC, C0, T1/2, CL and (Vd: 1383 μg*h/mL, 1.79 μg/mL, 1.2 hours, 3.49 L/h/kg, and 3.0 L/kg, respectively).HVR-19029 (25-75 mg/kg; I.p.; twice daily for 10 days) inhibits EBOV and MARV infection in mice[2].